UBS Initiates Coverage on Edwards Lifesciences (EW) with a Neutral
More News related to EW
- First Transcatheter Valve Cases in Japan Performed With Edwards SAPIEN Valve
- Edwards Lifesciences to Present at the Credit Suisse Annual Healthcare Conference
- Edwards Lifesciences (EW) and DexCom (DXCM) Annouce Receipt of CE Mark
- Edwards Lifesciences and DexCom Announce Receipt of CE Mark for Glucose Monitoring System
- Goldman Sachs Ups Edwards Lifesciences (EW) to Buy, On Product Cycle and Possible Take-Out; NUVA Downgraded
More News related to New Coverage
- Communications Systems (JCS) Reports Year-Over-Year Decline in Q3 Earnings
- Communications Systems (JCS) Posts Q3 EPS of $0.22, Down Y/Y
- Atmos Energy (ATO) Posts Q4 Loss of $0.17, Wider than Estimates
- China Digital TV (STV) Misses Q3 EPS by 2c; Guides Below for Q4
- Ralcorp (RAH) Misses Street's Q4 Views; Announces 7M Share Buyback
UBS initiates coverage on Edwards Lifesciences (NYSE: EW) with a Neutral rating.
To see more analyst ratings on EW Click Here.
Edwards Lifesciences Corporation (Edwards Lifesciences) is a global player in products and technologies designed to treat cardiovascular disease.
Related Categories
New CoverageStocks Mentioned
+0.18Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
